Department of Neurology, Haukeland University Hospital, Jonas Lies Vei 65, 5021, Bergen, Norway.
Curr Oncol Rep. 2023 Jul;25(7):787-792. doi: 10.1007/s11912-023-01410-8. Epub 2023 Apr 18.
The article gives an overview of the current knowledge in the management of tumor related epilepsy, including systematic reviews and consensus statements as well as recent insight into a potentially more individualized treatment approach.
Tumor molecular markers as IDH1 mutation and MGMT methylation status may provide future treatment targets. Seizure control should be included as a metric in assessing efficacy of tumor treatment. Prophylactic treatment is recommended in all brain tumor patients after the first seizure. Epilepsy has a profound effect on the quality of life in this patient group. The clinician should tailor the choice of seizure prophylactic treatment to the individual patient, with the goal of limiting adverse effects, avoiding interactions and obtaining a high degree of seizure freedom. Status epilepticus is associated with inferior survival and must be treated promptly. A multidisciplinary team should treat patients with brain tumors and epilepsy.
本文概述了肿瘤相关性癫痫的治疗现状，包括系统评价和共识声明，以及最近对潜在更个体化治疗方法的深入了解。
肿瘤分子标志物，如 IDH1 突变和 MGMT 甲基化状态，可能为未来的治疗提供靶点。在评估肿瘤治疗效果时，应将癫痫发作控制作为一个指标。所有脑肿瘤患者在首次癫痫发作后均应进行预防性治疗。癫痫对该患者群体的生活质量有深远影响。临床医生应根据个体患者的情况选择合适的预防癫痫发作的治疗方法，以限制不良反应、避免相互作用并获得高度的无癫痫发作状态。癫痫持续状态与生存率降低有关，必须及时治疗。多学科团队应治疗患有脑肿瘤和癫痫的患者。
